Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Core Insights - VolitionRx Limited announced the publication of a clinical study indicating that the Nu.Q® H3.1 biomarker can aid in assessing sepsis, organ failure, and subphenotypes in critically ill ICU patients [1][4] - The study involved 1713 patients and demonstrated that H3.1 nucleosomes are biologically specific markers of NETosis, with implications for prognostic enrichment and therapeutic targeting [2][5] - The findings suggest that H3.1 nucleosomes are associated with sepsis and organ dysfunction, highlighting their potential role in treating excessive NETosis in patients [3][4] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early detection and monitoring of diseases, including cancers and conditions related to NETosis [6][7] - The company aims to improve patient outcomes through earlier detection and monitoring, which can enhance both the quality and longevity of life for patients [7][8] - Volition's research and development activities are primarily based in Belgium, with additional operations in the U.S. and London [8]